Denali Therapeutics Announces Key Anticipated 2023 Milestones for Its Therapeutic Portfolio for Neurodegeneration and Lysosomal Storage Diseases
Four programs expected to progress in late-stage clinical studies for MPS II (Hunter syndrome), ALS,…
News
Calithera Biosciences Announces Board Approval of Complete Liquidation and Dissolution
SOUTH SAN FRANCISCO, Calif., Jan. 09, 2023 (GLOBE NEWSWIRE) — Calithera Biosciences, Inc. (Nasdaq: CALA),…
Helsinn announces the appointment of Dr Melanie Rolli as Group Chief Executive Officer
Helsinn announces the appointment of Dr Melanie Rolli as Group Chief Executive Officer – Giorgio…
ENA Respiratory Awarded $4.38 Million U.S. Department of Defense Agreement to Fund Development of Broad-Spectrum Antiviral INNA-051
— Goal is to add new medical countermeasure (MCM) against known and emerging viral respiratory…
AmMax Bio Enters into an Exclusive Option Agreement with Evopoint Biosciences to License a Next Generation Antibody Drug Conjugate (ADC) for the Treatment of Solid Tumors
This novel ADC is expected to have a wider therapeutic index and superior clinical profile…
TFF Pharmaceuticals Announces the Appointment of Zamaneh Mikhak, M.D. as Chief Medical Officer
FORT WORTH, Texas, Jan. 09, 2023 (GLOBE NEWSWIRE) — TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a…
Selecta Biosciences Provides Business Update and Outlook for 2023
– Expected topline data for Phase 3 DISSOLVE I & II programs of SEL-212 in…
Cogent Biosciences Announces Planned 2023 Milestones for Bezuclastinib and Emerging Portfolio of Selective and Potent Targeted Cancer Therapeutics
Demonstrate significant progress toward leadership in Systemic Mastocytosis (SM), including mid-year Part 1 results from…
Vaccinex Announces First Patient Dosed with Anti-CCR8 Antibody Licensed to Surface Oncology
Surface Oncology initiates clinical trial with antibody discovered using Vaccinex’s ActivMAb® Antibody Discovery Platform ROCHESTER,…
Biomea Fusion to Present at 41st Annual J.P. Morgan Healthcare Conference and Highlight 2023 Corporate Milestones
REDWOOD CITY, Calif., Jan. 09, 2023 (GLOBE NEWSWIRE) — Biomea Fusion, Inc. (Nasdaq: BMEA), a…
Kiniksa Pharmaceuticals Provides Corporate and Portfolio Update
– ARCALYST® (rilonacept) Q4 2022 and full-year 2022 net product revenue of $39.9 million and…
ORIC Pharmaceuticals Provides Corporate Update and Highlights Key Upcoming Milestones
Initial Phase 1b data for three ongoing clinical trials expected in second half of 2023: ORIC-533…
Cerevance Announces Positive Topline Data from Phase 1 Clinical Trial of CVN766 for the Potential Use in the Treatment of Schizophrenia
CVN766 was well tolerated with no serious adverse events CVN766, which has >1000-fold selectivity for…
Alimera Sciences Appoints Industry Veteran Russell L. Skibsted as Chief Financial Officer
Russel Skibsted 2MB Russell Skibsted, CFO of Alimera Sciences Russell Skibstead Hi-Res Russell Skibsted, CFO…
Rezo Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
SAN FRANCISCO, Jan. 09, 2023 (GLOBE NEWSWIRE) — Rezo Therapeutics, a biotechnology company pioneering the…
Theriva Biologics Announces Dosing of First Patient in the Investigator Sponsored Phase 1 Trial of VCN-01, an Intravenous Oncolytic Adenovirus, in Patients with Brain Tumors
-Clinical trial is being conducted at St. James’s University Hospital, United Kingdom, in collaboration with…
PROCEPT BioRobotics Announces Preliminary Fourth Quarter and Fiscal Year 2022 Revenue
PROCEPT BioRobotics to Report Fourth Quarter and Fiscal Year 2022 Financial Results on February 28,…
Achieve Life Sciences Announces Last Subject Dosed in Phase 3 ORCA-3 Trial of Cytisinicline for Smoking Cessation
SEATTLE, Wash and VANCOUVER, British Columbia, Jan. 09, 2023 (GLOBE NEWSWIRE) — Achieve Life Sciences,…
Krystal Biotech Announces FDA’s 3-Month Extension of BLA PDUFA Date and Regulatory Update for B-VEC to Treat Patients with Dystrophic Epidermolysis Bullosa
NEW PDUFA DATE OF MAY 19, 2023 PITTSBURGH, Jan. 09, 2023 (GLOBE NEWSWIRE) — Krystal…
Hepion Pharmaceuticals Receives $3.2 Million in Aggregate Non-Dilutive Funding
Approximately $2.9 Million from Sale of Its New Jersey State Net Operating Losses (“NOLs”), Plus…